A Szentágothai János Kutatóközpont a PTE korszerű, nemzetközi tudományszervezési és menedzsment normák szerint kialakított új intézménye, amely az élettudományi, élettelen természettudományi, valamint környezettudományi oktatás...
The research group is committed to advancing the field of systems neuroscience through rigorous basic and applied research. The objective of our research group is to adopt and further develop in vivo animal and human models of higher order mammalian brain function, with a particular focus on the identification of functional biomarkers associated with pathological mechanisms underlying neurodegenerative brain disorders, including Alzheimer's disease, schizophrenia and developmental spectrum disorders. Four laboratories provide a distinctive array of technical resources to facilitate interdisciplinary research within the same research group, from the neuron to the behavioral level. Furthermore, we facilitate the parallel comprehensive testing of the efficacy of novel cognitive enhancer drug candidates in preclinical experimental models. With regard to the research platform, the following avenues for research and development are available: applied systems neuroscience, drug development and validation; the development of novel in vivo testing techniques and methodology; the development of novel equipment for testing; neurophysiological testing of bioactive environmental (chemical and electromagnetic) agents; and formal education within the scope of the laboratories.
Applied systems neuroscience, drug development and validation
1. Small animal behavior laboratory (SZKK):
Open field test
Tadepalli, SA, Bali, ZK, Bruszt, N, Nagy, LV, Amrein, K, Fazekas, B, Büki, A, Czeiter, E, Hernádi, I (2020). Long-term cognitive impairment without diffuse axonal injury following repetitive mild traumatic brain injury in rats. Behav Brain Res 378:112268. doi:10.1016/j.bbr.2019.112268
Elevated Zero Maze (EOM)
Bali, ZK, Bruszt, N, Kőszegi, Z, Nagy, LV, Atlasz, T, Kovács, P, Csupor, D, Csupor-Löffler, B, Hernádi, I (2022) Aconitum Alkaloid Songorine Exerts Potent Gamma-Aminobutyric Acid-A Receptor Agonist Action In Vivo and Effectively Decreases Anxiety without Adverse Sedative or Psychomotor Effects in the Rat. Pharmaceutics. doi: 10.3390/pharmaceutics14102067
Novel object recognition (NOR) test
Tadepalli, SA, Bali, ZK, Bruszt, N, Nagy, LV, Amrein, K, Fazekas, B, Büki, A, Czeiter, E, Hernádi, I (2020). Long-term cognitive impairment without diffuse axonal injury following repetitive mild traumatic brain injury in rats. Behav Brain Res 378:112268. doi:10.1016/j.bbr.2019.112268
Morris water maze (MWM)
Bruszt, N, Bali, ZK, Tadepalli, SA, Nagy, LV, Hernádi, I (2021) Potentiation of cognitive enhancer effects of Alzheimer’s disease medication memantine by alpha7 nicotinic acetylcholine receptor agonist PHA-543613 in the Morris water maze task. Psychopharmacology. doi: 10.1007/s00213-021-05942-4
Psychomotor vigilance task (PVT)
Bali, ZK, Nagy, LV, Bruszt, N, Bodó, K, Engelmann, P, Hernádi, Z, Göntér, K, Tadepalli, SA, Hernádi, I (2023) Increased brain cytokine level associated impairment of vigilance and memory in aged rats can be alleviated by alpha7 nicotinic acetylcholine receptor agonist treatment. Geroscience: Official Journal Of The American Aging Association (Age). doi: 10.1007/s11357-023-01019-6
Spontaneous alternation test in a T-maze
Bali ZK, Bruszt N, Tadepalli SA, Csurgyók R, Nagy LV, Tompa M, Hernádi I (2019). Cognitive enhancer effects of low memantine doses are facilitated by an alpha7 nicotinic acetylcholine receptor agonist in scopolamine-induced amnesia in rats. Front Pharmacol 10:73. doi: 10.3389/fphar.2019.00073
2. In vivo cellular laboratory (TTK):
3. NHP research laboratory at the Grastyán Endre Translational Research Centre
4. Human psychophysiology laboratory (TTK):
